Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment
Open accessThe DOI matches its Crossref record; 134 of the 135 references it cites were found in a registry or an index.
Abstract
Myeloid-derived suppressor cells (MDSC) are a diverse population of immature myeloid cells that have potent immune-suppressive activity. Studies in both mice and humans have demonstrated that MDSC accumulate in most individuals with cancer, where they promote tumor progression, inhibit antitumor immunity, and are an obstacle to many cancer immunotherapies. As a result, there has been intense interest in understanding the mechanisms and in situ conditions that regulate and sustain MDSC, and the mechanisms MDSC use to promote tumor progression. This article reviews the characterization of MDSC and how they are distinguished from neutrophils, describes the suppressive mechanisms used by MDSC to mediate their effects, and explains the role of proinflammatory mediators and the tumor microenvironment in driving MDSC accumulation, suppressive potency, and survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 13×
“In contrast to STAT3, which promotes MDSC accumulation, IRF8 deters PMN-MDSC accumulation.”
BackgroundInfluentialCoordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Self-citationPolarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TAN
Fridlender, Z. G., Sun, J., Kim, S., Kapoor, V., Cheng, G., Ling, L., Worthen, G. S., & Albelda, S. M. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.017 · Cited by 3,371
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751 · cited 1×
“Because there has been considerable discussion about the nomenclature, phenotype, and function of this cell population, an international group of investigators in the field recently recommended nomenclature and characterization standards for MDSC (15).”
BackgroundSelf-citationThe Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Kumar, V., Patel, S., Tcyganov, E., & Gabrilovich, D. I. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.01.004 · Cited by 2,008
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Regulation of immune responses by L-arginine metabolism
Bronte, V., & Zanovello, P. (2005) · Nature Reviews Immunology · doi:10.1038/nri1668 · Cited by 1,775
Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer
Ostrand-Rosenberg, S., & Sinha, P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0802740 · Cited by 1,736 · cited 1×
“driving force for MDSC, and the hypothesis that one of the mechanisms by which inflammation drives cancer risk and tumor progression is through the suppression of antitumor immunity (47).”
Self-citationHuang, B., Pan, P.-Y., Li, Q., Sato, A. I., Levy, D. E., Bromberg, J., Divino, C. M., & Chen, S.-H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1299 · Cited by 1,435
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Research works printed but not linked: 1
- Geis-Asteggiante L 2017 Quantitative analysis of intact proteins and RNAs carried by immunosuppressive exosomes Ph.D. thesis University of Maryland
Cited by
Items 201–300 of 523
Golonka, R. M., & Vijay–Kumar, M. (2020) · Advances in cancer research · doi:10.1016/bs.acr.2020.10.004 · Cited by 29
Neutrophils in Tumorigenesis: Missing Targets for Successful Next Generation Cancer Therapies?
Tolle, F., Umansky, V., Utikal, J. S., Kreis, S., & Bréchard, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136744 · Cited by 28
Li, C., Zhang, X., Kang, X., Chen, C., Guo, F., Wang, Q., & Zhao, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01345 · Cited by 27
IL-31 induces antitumor immunity in breast carcinoma
Kan, T., Feldman, E., Timaner, M., Raviv, Z., Shen-Orr, S. S., Aronheim, A., & Shaked, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001010 · Cited by 28
Takizawa, S., Murao, A., Ochani, M., Aziz, M., & Wang, P. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3hi0620-416r · Cited by 29
Rueden, S. K. V., & Fan, T. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.773420 · Cited by 31
“MDSCs exert counterregulatory activities to impede exuberant T cell responses and can contribute to non-inflamed immune phenotypes (50).”
BackgroundRETRACTED: Coagulation and inflammation in cancer: Limitations and prospects for treatment
Singh, A. K., & Malviya, R. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188727 · Cited by 27
RetractedLeukemia’s Next Top Model? Syngeneic Models to Advance Adoptive Cellular Therapy
Zoine, J. T., Moore, S. E., & Velasquez, M. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.867103 · Cited by 28
Nourbakhsh, E., Mohammadi, A., Parizi, M. S., Mansouri, A., & Ebrahimzadeh, F. (2021) · Inflammopharmacology · doi:10.1007/s10787-021-00846-3 · Cited by 27
Resistance mechanisms to checkpoint inhibitors
Weiss, S. A., & Sznol, M. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.001 · Cited by 27
Chen, Y., He, F., Wang, R., Yao, M., Li, Y., Guo, D., & He, S. (2021) · BioMed Research International · doi:10.1155/2021/5954036 · Cited by 28
“Tumors mainly pass through two types of cells, regulatory T cells or Tregs and myeloid cells, called myeloid-derived suppressor cells (MDSC), which are immunosuppressive agents, which means that they secrete chemicals (such as cytokines) to inhibit infiltrating T cells [35].”
BackgroundCXC Chemokine Signaling in Progression of Epithelial Ovarian Cancer: Theranostic Perspectives
Huang, X., Hao, J., Tan, Y. Q., Zhu, T., Pandey, V., & Lobie, P. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052642 · Cited by 29
Myeloid-derived suppressor cells in COVID-19: A review
Perfilyeva, Y. V., Ostapchuk, Y. O., Tleulieva, R., Kali, A., Abdolla, N., Krasnoshtanov, V. K., Perfilyeva, A. V., & Belyaev, N. N. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109024 · Cited by 27
“No change in MMDSc and e-MDSC (proportion, in patients as compared to HD) No [72] 11 N = 61 (COVID19: 39 ICU; HD: 22) PB No Fresh PMN-MDSC: CRTH2− CD15+LOX1+CD10dimCD16dim Increase in PMNMDSC (proportion, in ICU patients as compared to HD) Inhibition of antigennonspecific T cell production of IFN-g [66] 12 N = 27 (COV…”
InfluentialMinaei, E., Ranson, M., Aghmesheh, M., Sluyter, R., & Vine, K. L. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.07.023 · Cited by 26
Zhu, W., Cheng, X., Xu, P., Gu, Y., Xu, H., Xu, J., Wang, Y., Zhang, L. W., & Wang, Y. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c05650 · Cited by 26
Toghraie, F. S., Bayat, M., Hosseini, M. S., & Ramezani, A. (2025) · Cellular Oncology · doi:10.1007/s13402-025-01051-y · Cited by 25
Abascal, J. W., Oh, M. S., Liclican, E. L., Dubinett, S. M., Salehi‐Rad, R., & Liu, B. (2023) · Cells · doi:10.3390/cells12192404 · Cited by 26
Mechanisms of anesthetic-induced immune dysregulation
Fagundes, T. R., Coradi, C., Sotomayor, M. R., Campos, A. G. H., da Silva, L. C. F., Ferneda, H. A., Pereira, W. D. S., Bellandi, G. B., Simonato, M. E. P., Steffanello, V. V., et al. (2025) · Anesthesiology and Perioperative Science · doi:10.1007/s44254-025-00117-2 · Cited by 25
“MDSCs are immature cells that represent a pathological state of activation and have immunosuppressive action, inhibiting both the activation and function of T and NK cells [66, 67].”
Kreps, L. M., & Addison, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062911 · Cited by 26
Lu, Z., Liu, H., Ma, L., Ren, K., He, Z., Li, M., & He, Q. S. (2022) · Nanoscale · doi:10.1039/d2nr03880c · Cited by 24
The role of myeloid-derived suppressor cells in hematologic malignancies
Gunes, E. G., Rosen, S. T., & Querfeld, C. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000662 · Cited by 24
“T-cell receptor nitrosylation results from increased levels of ROS in GMDSCs and it facilitates the suppression of T-cell proliferation and function [32,33].”
BackgroundMyeloid-derived suppressor cell cytokine secretion as prognostic factor in myelodysplastic syndromes
Han, D., Tao, J., Fu, R., & Shao, Z. (2020) · Innate Immunity · doi:10.1177/1753425920961157 · Cited by 24
“MDSCs are a heterogeneous population of immature myeloid cells with an immunosuppressive function in the tumour micro-environment.(8,9) The role of MDSCs in suppressing the immune system has been demonstrated in infection, chronic inflammation, autoimmune diseases, graft-versus-host disease,(10,11) many solid tumours…”
BackgroundNie, S.-C., Jing, Y., Lu, L., Ren, S.-S., Ji, G., & Xu, H.-C. (2024) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v16.i5.1690 · Cited by 23
“In humans, PMN-MDSCs and M-MDSCs can be distinguished by their respective markers: CD14-CD11b+CD15+CD66b+CD33+ HLA-DR-for PMN-MDSCs and CD14+CD11b+CD15-CD66b-CD33+HLA-DR-for M-MDSCs[41-43].”
Modulation of PD-1/PD-L1 axis in myeloid-derived suppressor cells by anti-cancer treatments
Jachetti, E., Sangaletti, S., Chiodoni, C., Ferrara, R., & Colombo, M. P. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104301 · Cited by 23
Xu, L., Cai, P., Li, X., Wu, X., Gao, J., Liu, W., Yang, J., Xu, Q., Guo, W., & Gu, Y. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115672 · Cited by 26
O’Melia, M. J., Mulero‐Russe, A., Kim, J., Pybus, A. F., DeRyckere, D., Wood, L. B., Graham, D. K., Botchwey, E. A., García, A. J., & Thomas, S. N. (2022) · Advanced Materials · doi:10.1002/adma.202108084 · Cited by 23
Jiang, M., Fiering, S., & Shao, Q. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1153066 · Cited by 23
Sinha, V. C., Rinkenbaugh, A. L., Xu, M., Zhou, X., Zhang, X., Jeter-Jones, S. L., Shao, J., Qi, Y., Zebala, J. A., Maeda, D. Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25240-z · Cited by 25
Engineering Bacteria as Living Therapeutics in Cancer Therapy
Chen, J., Chen, J., Chen, Y., Yuan, W., Zhang, J., Wang, G., & Dai, Z. (2025) · Advanced Science · doi:10.1002/advs.202507820 · Cited by 28
Cha, J., Chan, L.-C., Wang, Y., Chu, Y., Wang, C., Lee, H., Xia, W., Shyu, W., Liu, S., Yao, J., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101817 · Cited by 24
“Both TAMs and MDSCs are well known to suppress antitumor immunity (27, 28).”
BackgroundXie, Z., Kawasaki, T., Zhou, H., Okuzaki, D., Okada, N., & Tachibana, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.873792 · Cited by 23
“MDSCs play important roles in the suppression of antitumor immunity, resulting in the exacerbation of cancer (Fleming et al., 2018; Ostrand-Rosenberg and Fenselau, 2018; Veglia et al., 2021).”
BackgroundSankar, K. N., Pearson, A. N., Worlikar, T., Perricone, M. D., Holcomb, E. A., Mendiratta‐Lala, M., Xu, Z., Bhowmick, N. A., & Green, M. D. (2023) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh-23-11 · Cited by 23
“DCs isolated from HCC tumors express inhibitory receptor ligands including PD-1, T cell immunoglobulin and mucin-domain containing-3 (TIM-3), lymphocyte-activation gene 3 (LAG-3), and CTLA-4, leading to the inhibition of adaptive immunostimulatory responses (59).”
InfluentialPullen, N., Pickford, A. R., Perry, M. M., Jaworski, D. M., Loveson, K. F., Arthur, D., Holliday, J., Meter, T. E. V., Peckham, R., Younas, W., et al. (2018) · Metalloproteinases In Medicine · doi:10.2147/mnm.s105123 · Cited by 24
“N 2 neutrophils overlap functionally with but are likely a distinct population from polymorphonuclear myeloid-derived suppressor cells (MDSCs), which are also found in abundance in high-grade cancer cases.(198) Harnessing the fact that regardless of phenotype, neutrophils potently invade brain tumors, Xue et al recent…”
Top-Down Proteomic Characterization of Truncated Proteoforms
Chen, D., Geis‐Asteggiante, L., Gomes, F. P., Ostrand‐Rosenberg, S., & Fenselau, C. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00487 · Cited by 22
Self-citationZahran, A. M., Moeen, S. M., Thabet, A. F., Rayan, A., Abdel-Rahim, M. H., Mohamed, W. M. Y., & Hetta, H. F. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1728747 · Cited by 22
In situ vaccination with nanoparticles for cancer immunotherapy: understanding the immunology
Mao, C., Gorbet, M.-J., Singh, A., Ranjan, A., & Fiering, S. (2020) · International Journal of Hyperthermia · doi:10.1080/02656736.2020.1810333 · Cited by 22
Song, G., Zhang, Y., Tian, J., Ma, J., Yin, K., Xu, H., & Wang, S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.649020 · Cited by 24
Neutrophils in cancer—unresolved questions
Ng, M. S. F., Tan, L., Wang, Q., Mackay, C. R., & Ng, L. G. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1853-4 · Cited by 22
Wuren, T., Huecksteadt, T. P., Beck, E. M., Warren, K. J., Hoidal, J. R., Ostrand‐Rosenberg, S., & Sanders, K. A. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104379 · Cited by 24
Self-citationThe Role of Innate Immune Cells in Tumor Invasion and Metastasis
Huang, Y., Busuttil, R. A., & Boussioutas, A. (2021) · Cancers · doi:10.3390/cancers13235885 · Cited by 24
“Myeloid-derived suppressor cells (MDSC) are a diverse of population of immature myeloid cells found in the TME that have potent immune suppressive activity [115] and capacity to establish a tumor pre-metastatic niche [116].”
BackgroundKaczmarek, F., Marcinkowska‐Gapińska, A., Bartkowiak-Wieczorek, J., Nowak, M., Kmiecik, M., Brzezińska, K., Dotka, M., Brosz, P., Firlej, W., & Wojtyła-Buciora, P. (2025) · Cancers · doi:10.3390/cancers17122001 · Cited by 23
Battaglia, A., Buzzonetti, A., Fossati, M., Scambia, G., Fattorossi, A., Madiyalakan, M. R., Mahnke, Y. D., & Nicodemus, C. F. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02456-z · Cited by 21
Shioya, K., Matsumura, T., Seki, Y., Shimizu, H., Nakamura, T., & Taniguchi, S. (2021) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbaa057 · Cited by 21
Clinical Translation of Neutrophil Imaging and Its Role in Cancer
Lau, D., Lechermann, L. M., & Gallagher, F. A. (2021) · Molecular Imaging and Biology · doi:10.1007/s11307-021-01649-2 · Cited by 22
Sharma, V., Sachdeva, N. K., Gupta, V., Nada, R., Jacob, J., Sahni, D., & Aggarwal, A. (2022) · Immunobiology · doi:10.1016/j.imbio.2022.152210 · Cited by 21
Lee, J. Y., Nguyen, B., Mukhopadhyay, A., Han, M., Zhang, J., Gujar, R., Salazar, J. V., Hermiz, R., Svenson, L., Browning, E., et al. (2022) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2022.04.005 · Cited by 21
Wang, Y., Wang, J., Zhu, F., Wang, H., Yi, L., Huang, K., & Zhai, Z. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.616 · Cited by 23
“Under the effects of various factors secreted by tumor cells, MDSCs secreted a variety of proproliferative, proinflammatory, and immunosuppressive molecules via activating their own S1PR1‐STAT3, TGF‐β, and other signaling pathways, to make local blood vessels hyperpermeable, to build pre‐metastatic microenvironments,…”
BackgroundMarguier, A., Laheurte, C., Lecoester, B., Malfroy, M., Boullerot, L., Renaudin, A., Seffar, E., Kumar, A., Nardin, C., Aubin, F., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932298 · Cited by 21
Jakoš, T., Pišlar, A. H., Fonović, U. P., Švajger, U., & Kos, J. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02592-x · Cited by 21
Zahran, A. M., Hetta, H. F., Zahran, Z. A. M., Rashad, A., Rayan, A., Mohamed, D. O., Elhameed, Z. A. A., Khallaf, S., Batiha, G. E., Waheed, Y., et al. (2021) · Journal of Immunology Research · doi:10.1155/2021/3241150 · Cited by 21
“Phenotypically, these cells are defined by several markers; none of them is characteristic of MDSCs; the CD11b marker is expressed by all MDSCs [6]; there are two major subtypes of MDSCs; monocytic MDSCs express CD14, and polymorphonuclear MDSCs express CD15 and CD66b; both types express CD33 in addition to CD11b with…”
BackgroundThe role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies
Sheida, F., Razi, S., Keshavarz‐Fathi, M., & Rezaei, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2011224 · Cited by 21
“resistance to immune checkpoint inhibitors [46,206].”
Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS
Velegraki, M., Stiff, A. R., Papadaki, H. Α., & Li, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11164908 · Cited by 21
“The PMN-MDSCs and M-MDSCs have been shown to inhibit both innate and adaptive immune responses by a variety of mechanisms, and in many cases these mechanisms are shared between both subsets [14,15].”
BackgroundNachmany, I., Bogoch, Y., Sivan, A., Amar, O., Bondar, E., Zohar, N., Yakubovsky, O., Fainaru, O., Klausner, J. M., & Pencovich, N. (2019) · The FASEB Journal · doi:10.1096/fj.201801733r · Cited by 22
“In mice, MDSCs are generally identified by the coexpression of surface markers CD11b and Gr1 and divided into 2 subtypes, G-MDSCs and monocytic MDSCs, based on their distinct expression of Ly6G and Ly6C, respectively (25, 35).”
BackgroundLong Non-Coding RNA Hotairm1 Promotes S100A9 Support of MDSC Expansion during Sepsis.
Alkhateeb, T., Bah, I., Kumbhare, A., Youssef, D. A., Yao, Z. Q., McCall, C. E., & Gazzar, M. E. (2020) · PubMed · Cited by 23
Comparing thermal stress reduction strategies that influence MDSC accumulation in tumor bearing mice
MacDonald, C. R., Ministero, S., Pandey, M. R., Robinson, D. L., Hong, E. F., Hylander, B. L., McCarthy, P. L., Gordon, C. J., Repasky, E. A., & Mohammadpour, H. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104285 · Cited by 20
“MDSC populations are capable of shifting the delicate balance of this immune response from anti-tumor to pro-tumor [2], and it is likely that decreasing MDSC accumulation allows for improved therapeutic efficacy along with enhanced immune cell killing of tumor cells [30, 31].”
BackgroundCastillo, J. G., Fernandez, S., Campbell, T., Ventura, D. G., Williams, J. T., Ybarra, J., Hernandez, N. F., Wells, E., Portnoy, D. A., & DuPage, M. J. P. (2024) · Immunity · doi:10.1016/j.immuni.2025.05.001 · Cited by 21
The Role of Tumor Microenvironment in Triple-Negative Breast Cancer and Its Therapeutic Targeting
Vuletić, A. M., Martinović, K. M., & Jurišić, V. (2025) · Cells · doi:10.3390/cells14171353 · Cited by 19
Resistance and recurrence of malignancies after CAR-T cell therapy
Zeng, W., & Zhang, P. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112971 · Cited by 19
Basak, M., Chaudhary, D. K., Takahashi, R., Yamamoto, Y., Tiwari, S., Tahara, H., & Mittal, A. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00893 · Cited by 20
Dzierlega, K., Chakraborty, M., Lee, M., Soliman, A. M., Parker, D. J., Khan, S. M., Chan, Y. T., Akbari, M., Yokota, T., Winer, S., et al. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200064 · Cited by 19
Eosinophils can more than kill
Berek, C. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20181152 · Cited by 19
Sivagnanalingam, U., Beatty, P. L., & Finn, O. J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23206 · Cited by 20
“flammation, emergency myelopoiesis facilitates mobilization of MDSC, which is controlled by the C/EBPB transcription factor.(13) Pro‐ inflammatory mediators in the microenvironment, such as IL‐6 and IL‐1β help drive the accumulation and also influence the potency of”
BackgroundZheng, W., Zhu, Y., Chen, X., & Zhao, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2589 · Cited by 19
“Investigation of the functional characteristics and phenotypic characteristics of MDSCs may reveal the progression of HNSCC, how it spreads, and how to treat it (16).”
BackgroundZhan, X., He, Q., Sheng, J., Jiang, X., Lin, L., Huang, Y., He, S., Chen, Y., Li, L., Zeng, Z., et al. (2022) · Immunology · doi:10.1111/imm.13552 · Cited by 21
“MDSCs contribute to the establishment of an immunosuppressive microenvironment and promote tumour growth [26].”
BackgroundSánchez-León, M. L., Jiménez‐Cortegana, C., Silva-Romeiro, S., Garnacho, C., de la Cruz‐Merino, L., García-Domínguez, D. J., Hontecillas‐Prieto, L., & Sánchez‐Margalet, V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065208 · Cited by 19
Wang, Z., Du, X., Xing, X., Xie, W., Xin, H., & Liu, W. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0251 · Cited by 19
Nitrogen-Doped Carbon Nanotube Cups for Cancer Therapy
Burkert, S. C., He, X., Shurin, G. V., Nefedova, Y., Kagan, V. E., Shurin, M. R., & Star, A. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c03245 · Cited by 18
Chen, P., Li, Y., Liu, R., Xie, Y., Jin, Y. T., Wang, M., Yu, Z., Wang, W., & Luo, X. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101594 · Cited by 18
Wang, L., Duan, Y., Lu, S., & Sun, J. (2023) · Journal of Functional Biomaterials · doi:10.3390/jfb14020058 · Cited by 18
Multiomics Empowers Predictive Pancreatic Cancer Immunotherapy
Montagne, J. M., Jaffee, E. M., & Fertig, E. J. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200660 · Cited by 19
Daneshmandi, S., Qi, Y., Choi, J. E., Katsuta, E., MacDonald, C. R., Goruganthu, M., Roberts, N. T., Repasky, E. A., Singh, P. K., Attwood, K. M., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01187-1 · Cited by 19
“They are commonly described as either monocytic MDSCs (M-MDSCs) (resembling immature monocytes) or polymorphonuclear MDSCs (PMN-MDSCs) (resembling immature neutrophils) [3, 4].”
Domka, K., Góral, A., & Firczuk, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01538 · Cited by 21
Immune Checkpoints in Pediatric Solid Tumors: Targetable Pathways for Advanced Therapeutic Purposes
Cocco, C., Morandi, F., & Airoldi, I. (2021) · Cells · doi:10.3390/cells10040927 · Cited by 18
“The cytokines released mainly promote an immune-suppressive microenvironment where IL-10 and TGF-β1 play a crucial role.”
BackgroundInfluentialMyeloid-derived suppressor cells and vaccination against pathogens
Prochetto, E., Borgna, E., Jiménez‐Cortegana, C., Sánchez‐Margalet, V., & Cabrera, G. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.1003781 · Cited by 19
“, 2009); H) production of exosomes (Ostrand-Rosenberg and Fenselau, 2018); I) transfer of oxidatively truncated lipids (Ugolini et al.”
BackgroundO’Leary, K. A., Bates, A. M., Jin, W. J., Burkel, B. M., Sriramaneni, R. N., Emma, S. E., Nystuen, E. J., Sumiec, E. G., Ponik, S. M., Morris, Z. S., et al. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01671-y · Cited by 19
“However, RT not only increases anti-tumor immunity, but also increases immunosuppressive immune cell subpopulations such as MDSCs and Tregs [11–13, 17].”
BackgroundInfluentialADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression
Sheldon, H., Bridges, E., Silva, I., Masiero, M., Favara, D. M., Wang, D., Leek, R., Snell, C. E., Roxanis, I., Kreuzer, M., et al. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0171 · Cited by 17
“Antitumor immunity is also regulated by key cell populations, such as MDSCs that have an important immune-suppressive function (36).”
BackgroundTheron, A. J., Steel, H. C., Rapoport, B. L., & Anderson, R. (2020) · Pharmaceuticals · doi:10.3390/ph13110406 · Cited by 17
Human splenic myeloid derived suppressor cells: Phenotypic and clustering analysis
Cole, K., Ly, Q. P., Hollingsworth, M. A., Cox, J. L., Padussis, J. C., Foster, J. M., Vargas, L. M., & Talmadge, J. E. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104317 · Cited by 17
Yu, J., Li, H., Zhang, Z., Lin, W., Wei, X., & Shao, B. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.647312 · Cited by 20
Pelosi, A., Besi, F., Tumino, N., Merli, P., Quatrini, L., Pira, G. L., Algeri, M., Moretta, L., & Vacca, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.657329 · Cited by 18
“Circulating and tumor-infiltrating PMN-MDSCs have a short in vivo lifespan, whereas during inflammation the half-life of PMN-MDSCs may be significantly prolonged (39).”
BackgroundHofstee, M. I., Riool, M., Gieling, F., Stenger, V., Constant, C., Nehrbass, D., Zeiter, S., Richards, R. G., Zaat, S. A. J., & Moriarty, T. F. (2021) · European Cells and Materials · doi:10.22203/ecm.v041a49 · Cited by 17
“MDSCs suppress other immune cells by upregulating iNOS and/or Arg-1 and releasing molecules including ROS, IL-10, TGF-β and PGE2 to promote e.g. Treg and regulatory B cell induction (Ostrand-Rosenberg and Fenselau, 2018; Veglia et al., 2018).”
BackgroundInfluentialEvolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective
Bleve, A., Consonni, F. M., Porta, C., Garlatti, V., & Sica, A. (2022) · Cancers · doi:10.3390/cancers14030510 · Cited by 21
Ishitobi, K., Kotani, H., Iida, Y., Taniura, T., Notsu, Y., Tajima, Y., & Harada, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109423 · Cited by 17
Tao, L., Cheng, G., Lv, F., Wang, R. L., Yang, N., Xing, Z., Gu, B., Meng, S., Xu, W., & Huo, M. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.145092 · Cited by 17
Sharma, V., Aggarwal, A., Jacob, J., & Sahni, D. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13021 · Cited by 16
Shokati, E., & Safari, E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110267 · Cited by 16
Synergistic effect of adoptive immunotherapy and docetaxel inhibits tumor growth in a mouse model
Hu, Y., Liu, J., Cui, P., Liu, T., Piao, C., Xu, X., Zhang, Q., Xiao, M., Lu, Y., Liu, X., et al. (2019) · Cellular Immunology · doi:10.1016/j.cellimm.2019.104036 · Cited by 16
Gonçalves, B. Ô. P., Fialho, S. L., Silvestrini, B. R., Sena, I. F. G., Santos, G. S. P., Gomes, D. A., & Silva, L. M. (2020) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2020.104520 · Cited by 16
c-Rel-dependent monocytes are potent immune suppressor cells in cancer
Li, T., Bou-Dargham, M. J., Fultang, N., Li, X., Pear, W. S., Sun, H., & Chen, Y. H. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ma0422-518rr · Cited by 15
Alberti, G., Arsuffi, C., Pievani, A., Salerno, D., Mantegazza, F., Dazzi, F., Biondi, A., Tettamanti, S., & Serafini, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192333 · Cited by 15
Molecular Genealogy of Metabolic-associated Hepatocellular Carcinoma
Kodama, T., & Takehara, T. (2024) · Seminars in Liver Disease · doi:10.1055/a-2289-2298 · Cited by 16
“72 In the obese background, high levels of cholesterol induce lipid peroxidation in NKT cells and impair their tumor-suppressive effects, which is cancelled by statin treatment in an experimental mouse model.”
Immunostimulatory functions of adoptively transferred MDSCs in experimental blunt chest trauma
Kustermann, M., Klingspor, M., Huber-Lang, M. S., Debatin, K., & Strauß, G. (2019) · Scientific Reports · doi:10.1038/s41598-019-44419-5 · Cited by 15
Kowalska, W., & Bojarska-Junak, A. A. (2020) · Folia Histochemica et Cytobiologica · doi:10.5603/fhc.a2020.0006 · Cited by 15
“Gustafson et al. [31] reported that the abundance of CD14+HLA-DRlo cells is associated with a shorter time to CLL progression.”
BackgroundInfluentialEmerging roles for myeloid immune cells in bone metastasis
Alsamraae, M., & Cook, L. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09965-3 · Cited by 16
“further categorized into granulocytic/polymorphonuclear (PMNMDSCs) or monocytic (M-MDSCs) and both subtypes suppress anti-tumor immunity and promote tumor growth [93].”
BackgroundShahsavani, M. B., Heidari, M., Yousefi, R., & Moosavi‐Movahedi, A. A. (2025) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70208 · Cited by 16
Tumor microenvironment regulation by reactive oxygen species-mediated inflammasome activation
Jang, J., Kim, D.-H., & Chun, K. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01532-6 · Cited by 15
“Myeloid-derived suppressor cells (MDSCs) are a key immunosuppressive subset within TME, displaying strong immune-suppressive and tumor-promoting activities (Ostrand-Rosenberg and Fenselau 2018; Zou and Green 2023; Deng et al. 2024; Mei et al. 2024).”
New Discovery of Myeloid-Derived Suppressor Cell’s Tale on Viral Infection and COVID-19
Park, S., Nam, D., Seong, H. C., & Hahn, Y. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842535 · Cited by 14
“A positive correlation was found between PMN-MDSC and the concentration level of inflammatory cytokines (IL-1b, IL-6, IL-8, and TNF-a) in the FIGURE 1 | Molecular mechanisms of MDSCs on the immune system.”
BackgroundInfluentialTran, T., Lavillegrand, J., Lerévérend, C., Esposito, B., Cartier, L., Montabord, M., Tran-Rajau, J., Diedisheim, M., Gruel, N., Ouguerram, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33034-0 · Cited by 16
Myeloid-derived suppressor cells in head and neck squamous cell carcinoma
He, J.-Y., Huo, F., Tang, H., Liu, B., & Bu, L. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2022.11.002 · Cited by 15
Anderson, R., Blidner, A. G., & Rapoport, B. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.676399 · Cited by 14
“Targeting TGF-β1 Although immunosuppressive granulocytic MDSCs and N2 neutrophils appear to share a common identity, this issue remains unresolved (Ostrand-Rosenberg and Fenselau, 2018).”
Background
Metadata
- Authors
- Ostrand-Rosenberg, S., & Fenselau, C.
- Affiliations
- Department of Biological Sciences, University of Maryland Baltimore County , Baltimore, MD 21250
- University of Maryland, College Park (US)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-01
- Volume
- 200
- Issue
- 2
- Pages
- 422-431
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- PMC
- PMC5765878
- OpenAlex
- W2783633531
- Cited by
- 509
- References
- 135
- Citations by year
- 2026: 34 · 2025: 42 · 2024: 44 · 2023: 61 · 2022: 71 · 2021: 117 · 2020: 80 · 2019: 39 · 2018: 21
- FWCI
- 6.57
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Maryland Shared Open Access Repository (USMAI Consortium) (submittedVersion)
- Digital Repository at the University of Maryland (University of Maryland College Park)
- Funders
- National Institutes of Health (1s10od019938-01, RO1 GM021248)
- National Cancer Institute (R01CA084232, R01CA115880)
- National Institute of General Medical Sciences (R01GM021248)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- myeloid-derived suppressor cells, tumor immunosuppression, antitumor immunity, tumor microenvironment, pro-inflammatory mediators, neutrophils, cancer immunotherapy resistance, tumor progression
- MeSH terms
- Myeloid-Derived Suppressor Cells, Animals, Humans, Neoplasms, Phenotype, Cytokines, Disease Progression, Inflammation Mediators, Immunomodulation, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.